Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...

The crucial drugs can have unintended consequences. Innovative therapies could shield the microbiome from their effects.

A wide range of etiologies and pathogenic mechanisms underlie colitis. This Review provides an overview of the pathophysiology, epidemiology, histopathology, and clinical characteristics of ...

This indicator covers the incidence of healthcare associated infections from Clostridium difficile (C. diff). It measures outcomes that reflect the quality of care or processes linked by evidence to ...

In vitro, nitazoxanide has shown excellent activity against C. difficile. In one study, the 90% MIC (MIC 90) of the toxigenic strains of C. difficile was 0.5 µg/mL for nitazoxanide, which was ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...

Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

Video content above is prompted by the following: What are the common comorbidities seen with recurrent C difficile infections and how can they alter the treatment of the patient?